Literature DB >> 19449116

Editorial comment.

Michele Pavone-Macaluso.   

Abstract

Mesh：

Year:  2009        PMID： 19449116     DOI： 10.1007/s11255-009-9582-5

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


× No keyword cloud information.
  12 in total

1.  The role of neoadjuvant or adjuvant chemotherapy for invasive bladder cancer Is there a benefit for survival or preserving the bladder?

Authors:  M Pavone-Macaluso; R R Hall; Y Hirao; S Kamidono; N Miyanaga; P H de Mulder; S Naito; W U Shipley; T Tsushima
Journal:  Urol Oncol       Date:  1998 Jul-Oct       Impact factor: 3.498

Review 2.  What are the risks of cystectomy and the advances in perioperative care?

Authors:  J E Montie; M Pavone-Macaluso; H Tazaki; W Albrecht; A Bono; P Karthaus; N Miyanaga; T Ueda; A von Eschenbach
Journal:  Int J Urol       Date:  1995-06       Impact factor: 3.369

3.  The effects of neoadjuvant chemotherapy and chemo-radiation therapy on MRI staging in invasive bladder cancer: comparative study based on the pathological examination of whole layer bladder wall.

Authors:  Kazushige Nishimura; Chisato Fujiyama; Keiji Nakashima; Yuji Satoh; Yuji Tokuda; Jiro Uozumi
Journal:  Int Urol Nephrol       Date:  2009-04-25       Impact factor: 2.370

4.  Neoadjuvant chemotherapy plus cystectomy compared with cystectomy alone for locally advanced bladder cancer.

Authors:  H Barton Grossman; Ronald B Natale; Catherine M Tangen; V O Speights; Nicholas J Vogelzang; Donald L Trump; Ralph W deVere White; Michael F Sarosdy; David P Wood; Derek Raghavan; E David Crawford
Journal:  N Engl J Med       Date:  2003-08-28       Impact factor: 91.245

5.  Outcome of patients with bladder cancer with pN+ disease after preoperative chemotherapy and radical cystectomy.

Authors:  Wassim Kassouf; Piyush K Agarwal; H Barton Grossman; Dan Leibovici; Mark F Munsell; Arlene Siefker-Radtke; Louis L Pisters; David A Swanson; Colin P N Dinney; Ashish M Kamat
Journal:  Urology       Date:  2008-10-09       Impact factor: 2.649

6.  A European Organization for Research and Treatment of Cancer--Genitourinary Group phase 2 study of chemotherapy in stage T3-4N0-XM0 transitional cell cancer of the bladder: evaluation of clinical response.

Authors:  T A Splinter; M Pavone-Macaluso; D Jacqmin; J T Roberts; P Carpentier; M de Pauw; R Sylvester
Journal:  J Urol       Date:  1992-12       Impact factor: 7.450

7.  Effect of combined therapy using balloon-occluded arterial infusion of cisplatin and hemodialysis with concurrent radiation for locally invasive bladder cancer.

Authors:  Haruhito Azuma; Yatsugu Kotake; Kazuhiro Yamamoto; Takeshi Sakamoto; Satoshi Kiyama; Takanobu Ubai; Teruo Inamoto; Kiyoshi Takahara; Mitsuru Matsuki; Naoki Segawa; Nobuhisa Shibahara; Yoji Katsuoka
Journal:  Am J Clin Oncol       Date:  2008-02       Impact factor: 2.339

Review 8.  Neoadjuvant and adjuvant chemotherapy in muscle-invasive bladder cancer.

Authors:  Fabio Calabrò; Cora N Sternberg
Journal:  Eur Urol       Date:  2008-10-16       Impact factor: 20.096

9.  Bladder preservation in selected patients with muscle-invasive bladder cancer by complete transurethral resection of the bladder plus systemic chemotherapy: long-term follow-up of a phase 2 nonrandomized comparative trial with radical cystectomy.

Authors:  Eduardo Solsona; Miguel A Climent; Inmaculada Iborra; Argimiro Collado; José Rubio; José V Ricós; Juan Casanova; Ana Calatrava; Jose L Monrós
Journal:  Eur Urol       Date:  2008-08-15       Impact factor: 20.096

10.  Can patient selection for bladder preservation be based on response to chemotherapy?

Authors:  Cora N Sternberg; Vito Pansadoro; Fabio Calabrò; Sylvia Schnetzer; Diana Giannarelli; Paolo Emiliozzi; Francesco De Paula; Paolo Scarpone; Piero De Carli; Maurizio Pizzo; Andrea Platania; Mostafà Amini
Journal:  Cancer       Date:  2003-04-01       Impact factor: 6.860
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.